about
Chronic hepatitis C in the state prison system: insights into the problems and possible solutionsOutcomes of treatment for hepatitis C virus infection by primary care providersPromoting HCV treatment completion for prison inmates: New York State's hepatitis C continuity programHepatitis C virus infection and prisoners: Epidemiology, outcome and treatmentViral hepatitis in Hawai'i--differing perspectivesTesting for sexually transmitted infections and blood borne viruses on admission to Western Australian prisonsUndiagnosed hepatitis C on the general medicine and trauma services of two urban hospitalsHCV-related mortality among male prison inmates in Texas, 1994-2003.Liver cancer mortality among male prison inmates in Texas, 1992-2003.Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis CHepatitis C in European prisons: a call for an evidence-informed responseControversies in and challenges to our understanding of hepatitis C.Prisoner survival inside and outside of the institution: implications for health-care planningA "one-two punch" leading to hepatitis C seroconversion.HCV infected prisoners: should they be still considered a difficult to treat population?Prevalence and epidemiological correlates and treatment outcome of HCV infection in an Italian prison setting.HIV and incarceration: prisons and detention.Personality disorders do not affect treatment outcomes for chronic HCV infection in Spanish prisoners: the Perseo studyComparison of hepatitis C virus treatment between incarcerated and community patientsTreating hepatitis C in American Indians/Alaskan Natives: A survey of Project ECHO(®) (Extension for Community Healthcare Outcomes) utilization by Indian Health Service providers.Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort studyHCV in incarcerated populations: an analysis of gender and criminality on riskClinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populationsPrevention of Hepatitis C by Screening and Treatment in U.S. Prisons.Hepatitis C among clients of health care for the homeless primary care clinicsPrisons and HCV: a review and a report on an experience in New South Wales Australia.Treating hepatitis C in the prison population is cost-saving.Viral hepatitis in incarcerated adults: a medical and public health concern.Impact of new therapeutics for hepatitis C virus infection in incarcerated populations.Hepatitis C seroprevalence among prison inmates since 2001: still high but declining.High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C.Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting.The cost-effectiveness of screening and treatment for hepatitis C in prisons in England and Wales: a cost-utility analysis.Targeted hepatitis C screening among ex-injection drug users in the community.High variability of TB, HIV, hepatitis C treatment and opioid substitution therapy among prisoners in Germany.The continuum of hepatitis C care for criminal justice involved adults in the DAA era: a retrospective cohort study demonstrating limited treatment uptake and inconsistent linkage to community-based care.Genotype distribution and treatment response among incarcerated drug-dependent patients with chronic hepatitis C infection.A Guide to the Economics of Hepatitis C Virus Cure in 2017Expert opinion on the management of hepatitis C infection in Kuwait
P2860
Q22305936-DAA94A2C-FEF5-4B25-805D-C87BDDE25711Q24601722-C90ABDA2-652A-4DD8-88A0-44EDB963C512Q24676385-9A418B0B-5368-4AA5-AA55-7D8955AB3954Q26785981-9F609596-4FDA-4452-A40D-846EE5D35508Q28729042-D340F4D8-514B-4D60-9037-2661BEE7E3AEQ33510258-D41B9428-F9A3-4E8E-990D-1C34390CC081Q33607231-946728EF-F4AC-4BAD-9298-A4712818D2CDQ33802968-325150C9-0AEA-451F-B4EA-06F32BED6A5CQ33889865-82986B67-625D-4620-9658-5477AC5DA444Q34113801-1C615B28-009F-4CBA-9E0B-49EBDD2A3A0CQ34260664-F9AA9004-9961-4FE4-B201-E3056A3786DAQ34604806-C114D436-F300-44C2-824B-D4A28531714BQ34605531-D753112D-9965-40CA-8637-FE0C5B3E315BQ34699080-71F758AC-E99A-401E-B14C-06775F4B73C1Q34941459-61B60F61-BC9E-4C27-8ADB-610948DD62AEQ35020696-250980E0-A10D-46ED-8995-D9E6AB8CEC14Q35068308-D02229B3-B6C4-453B-9CBD-AC86B893CA20Q35749560-7B0F3CBD-8A4E-4507-9876-208AD396E839Q35915031-E2C73264-4DFA-4D49-BD11-58CD0A4D80A5Q36372208-F0AA5519-D2DC-427A-BC6B-F5D775B647EEQ36733568-E927312A-282E-4CDC-98DD-E32AF0E250B7Q36837175-8F54AE22-CEF1-4EF0-973E-A38378B0265CQ36843554-AE3D17C4-53E5-4EF5-8049-D80F490A2A50Q36862066-877FC666-E253-4614-8809-AB781A62FC07Q37206722-8ED94B07-69A4-4E2F-B08E-AC55736CEA43Q37242489-87265EC8-2210-4DE0-88D6-C11DC6D7CF94Q37299503-D4C7E665-935D-4DC8-B064-05BBB7CA9557Q37400580-15D0B5CA-39CE-43D1-A8D8-61D229753916Q37419326-E65D509B-C96B-427C-B360-6A088E8AFD43Q37525298-80AE3E0C-EDA2-4EC1-A912-79CB446918F6Q37769280-C2B2CC69-2823-4DA6-97E6-97EB4862C3D5Q38077758-FECB5480-7771-4154-8021-9BBF10EFF798Q40069355-825DA8D6-A7B6-4B03-AB83-5A808A391B73Q42269922-6533FFE8-BB15-45A7-9D7D-C1186BCBDEE0Q42634287-209F7ED2-1C03-4FFA-8603-25CB99CD3563Q47115868-67BB4E80-3B31-49E5-BAD7-0B3E1B1A1FF8Q47547173-4E7231F6-49BE-4EEE-924B-172C698DBF9EQ56654943-A6C11BD1-147A-410C-9676-A334A35BDE9EQ57490314-967469CA-A9FD-4F8E-904A-840D1C75EE0D
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
A framework for management of hepatitis C in prisons.
@ast
A framework for management of hepatitis C in prisons.
@en
type
label
A framework for management of hepatitis C in prisons.
@ast
A framework for management of hepatitis C in prisons.
@en
prefLabel
A framework for management of hepatitis C in prisons.
@ast
A framework for management of hepatitis C in prisons.
@en
P2093
P1476
A framework for management of hepatitis C in prisons.
@en
P2093
Anne C Spaulding
Cindy M Weinbaum
Daryl T-Y Lau
Harold S Margolis
Jay H Hoofnagle
Leonard B Seeff
Richard Sterling
P304
P356
10.7326/0003-4819-144-10-200605160-00010
P407
P577
2006-05-01T00:00:00Z